To evaluate the efficacy of treatment options to reduce osteoporotic fracture risk in men. DESIGN: Systematic review and meta-analysis. SETTING: Randomized clinical trials that evaluated the efficacy of a treatment for osteoporosis or low bone mineral density for adult men and reported fracture outcomes. PARTICIPANTS: Men. MEASUREMENTS: PubMed, Embase, and the Cochrane Library databases were searched for relevant studies. Information was extracted from included studies on participant sociodemographic characteristics, number of male participants, treatment evaluated, comparator for evaluated treatment, study duration, and fracture outcomes. Risk of bias of individual studies was assessed using measures recommended by the Cochrane Collaboration. RESULTS: Twenty-four articles reporting results for 22 studies (including 4,868 male participants) met strict inclusion criteria. 1 and approximately one in five white men will sustain an osteoporotic fracture in his lifetime.
O steoporosis affects 2 million men in the United States, 1 and approximately one in five white men will sustain an osteoporotic fracture in his lifetime. 2 Men are estimated to incur 29% of all osteoporotic fractures and account for 25% of total osteoporosis-related costs. 3 Furthermore, men have higher mortality after hip fracture than women, with nearly one in three men aged 65 and older who incur a hip fracture dying within the following year. 4 The morbidity, mortality, and costs secondary to osteoporotic fractures in the United States are considerable and are likely to increase in upcoming years with the aging of the population. [2] [3] [4] [5] [6] [7] [8] [9] Despite the prevalence of osteoporosis in older men and the potential severity of its health consequences, osteoporosis in men is significantly less studied than in women; most osteoporosis clinical studies have not included male participants. 10 Osteoporosis treatments for men that the Food and Drug Administration (FDA) has approved include alendronate, risedronate, zoledronic acid, teriparatide, and denosumab, and several organizations have recommended osteoporosis treatment for men. 11, 12 A systematic review and meta-analysis of the evidence for fracture risk reduction for different osteoporosis treatment options for men was performed.
METHODS

Data Sources and Search Strategies
Broad literature search strategies were developed for the PubMed, Embase, and Cochrane Library databases to locate randomized clinical trials reporting the efficacy of osteoporosis treatment options. Initial literature searches were performed on August 15, 2014, for Embase; August 28, 2014, for PubMed; and November 28, 2014, for the Cochrane Library. The PubMed search was updated on March 18, 2016. The database search strategies are available upon request. Additional studies were identified by reviewing the reference lists of topical review articles and studies meeting the inclusion criteria and studies identified by experts.
Study Selection
Inclusion and exclusion criteria were applied to literature identified with the search strategies to select studies of interest. Studies that evaluated the efficacy of a treatment for adults with osteoporosis or low bone mineral density (BMD), were randomized clinical trials, reported separate data for male participants or had male participants only, and reported fracture outcomes with provision of numbers or percentages of men in each study group who sustained incident fractures were included. Studies published in any language were included, and there were no restrictions on study participant comorbidities. Studies in which not all participants were identified as having osteoporosis or low BMD (T-score ≤À1) were excluded. Studies were evaluated for inclusion in two stages-first titles and abstracts were reviewed, followed by full-text review of studies identified as potentially relevant after title and abstract review.
Data Extraction
Information was extracted from eligible studies on participant sociodemographic characteristics, number of male participants, study location, treatments/interventions evaluated, comparator for evaluated treatments/interventions, duration of study and follow-up for fracture outcomes, fracture outcomes evaluated, and results reported for fracture outcomes in intervention and comparator groups. For fracture outcomes, data were extracted on numbers of participants in the intervention and comparator groups who sustained incident fractures.
Data Analysis
Included study characteristics and study quality were qualitatively described. For study quality assessment, measures that the Cochrane Collaboration has recommended for assessing risk of bias for individual studies were used, including criteria to evaluate risk of selection, performance, detection, attrition, and reporting biases. 13 Fixed-effects meta-analyses were also conducted using the Mantel-Haenszel method 14 to calculate summary relative risk (RR) of fracture estimates for each treatment option for which there were at least two studies with similar comparators and fracture outcomes assessed and for bisphosphonates when considered as a treatment category. Between-study heterogeneity in each meta-analysis was assessed using I 2 values. For studies that reported fracture outcomes for multiple follow-up periods, the fracture outcomes reported for the longest follow-up time period were used when performing meta-analyses. For meta-analyses that included three or more studies, influence (sensitivity) analysis in which individual studies were excluded one at a time to assess whether meta-analysis findings were robust to exclusion of individual studies were also performed. Stata version 11.0 (Stata Corp., College Station, TX) was used to perform these analyses.
RESULTS
Literature Search and Study Selection
The literature searches identified 6,475 records (citations) for review; 2,673 of these were excluded because they were duplicates (same citation found in different databases), leaving 3,802 unique records for review. Twentyfour of these records reporting results for 22 different studies met inclusion criteria.
15-38 Figure 1 shows a flow diagram of the literature search and study selection.
Study Characteristics
Supplementary Table S1 shows included study characteristics. Included studies were published between 1998 and 2013, number of male study participants ranged from 23 to 1199, and study duration ranged from 1 to 3 years. Approximately half of the included studies evaluated the efficacy of bisphosphonate medications, with more studies assessing alendronate or zoledronic acid than other bisphosphonates. Most included studies compared a treatment option with placebo, calcium and vitamin D, or both; very few had active comparators. A majority of studies included only men with primary osteoporosis, hypogonadal osteoporosis, or both and did not include men with other causes of secondary osteoporosis. Many of the included studies had largely white participant populations. Commonly assessed osteoporosis fracture outcomes included all vertebral fractures (morphometric-detected using X-rays, including asymptomatic and symptomatic vertebral fractures), clinical vertebral fractures (symptomatic vertebral fractures only), nonvertebral fractures, and clinical fractures (clinically symptomatic fractures at any site). Vertebral fractures were the most commonly assessed fracture outcomes, followed by nonvertebral fractures and clinical fractures.
Only one included study, a study evaluating zoledronic acid therapy, reported having sufficient statistical power for fracture outcomes for men, for the outcome of morphometric vertebral fractures. 36 Only four studies reported RR, odds ratio, or hazard ratio of fracture comparing men in the intervention groups with the comparator groups; 17, 18, 29, 30, 35, 36 of these, three studies evaluating alendronate, risedronate, and zoledronic acid reported a statistically significantly lower risk of fracture in men receiving the evaluated intervention or treatment than in the comparison group-all for the outcome of vertebral fractures 18, 29, 30, 36 -and only one study evaluating risedronate for the outcome of nonvertebral fractures. 30 Only two included studies performed head-to-head comparisons of drugs that the FDA has approved for men -one study that compared teriparatide with alendronate 33 and another study that compared zoledronic acid with alendronate; 38 neither of these studies reported RR of fracture outcomes. Most studies reported pharmaceutical company funding. 15, 16, 19, [21] [22] [23] [24] [25] 27, 28, 31, [33] [34] [35] [36] 38 Study Quality and Potential Sources of Bias Supplementary Table S2 shows findings of the assessment of included study quality using criteria that the Cochrane Collaboration has recommended for assessing risk of bias for individual studies. In general, studies did not sufficiently describe their methods of random sequence generation, allocation concealment, or whether all prespecified outcomes in the study protocol were reported on in the prespecified way to permit judgment of low or high risk of bias for these domains. Thus, most studies were assessed as unclear risk of bias for the categories of selection bias and reporting bias. A majority of studies reported blinding of fracture outcome assessment and thus were assessed as being at low risk of detection bias. Studies were mixed with respect to domains of reporting of blinding of participants and personnel and incomplete outcome data, which fall within categories of performance bias and attrition bias, respectively. No included study was assessed as being at low risk of bias for all evaluated domains, so no study received a summary assessment of low risk of bias. A slight majority of studies received a summary assessment of high risk of bias (due to at least one bias domain being assessed as high risk of bias), with the remainder of the studies receiving a summary assessment of unclear risk of bias. The meta-analysis finding that bisphosphonates significantly reduce risk of vertebral fractures was robust to influence analysis, with summary estimates of RR of vertebral fractures with bisphosphonate therapy ranging from 0.353 to 0.391 with removal of individual studies and the lower limit of the 95% CI ranging from 0.215 to 0.265 and the upper limit of the 95% CI ranging from 0.518 to 0.594 with removal of individual studies. However, the finding that bisphosphonates significantly reduce risk of nonvertebral fractures was sensitive to removal of one study that evaluated risedronate therapy for men. 30 When this study was removed from the analysis, the summary estimate for RR of nonvertebral fractures with bisphosphonate therapy was 0.715 (95% CI = 0.382-1.337). The meta-analysis findings of nonsignificant reduction in the RR of clinical vertebral fractures or clinical fractures with bisphosphonates were robust to influence analysis, with results remaining nonsignificant with removal of any individual study in either analysis.
DISCUSSION
Relatively few randomized clinical trials have been performed to assess efficacy of osteoporosis treatment options for reducing fracture risk for men. These meta-analysis findings for individual treatment options demonstrated that alendronate and risedronate significantly reduce risk of vertebral fracture for men; however, the meta-analyses for individual treatment options did not demonstrate evidence of statistically significantly lower vertebral fracture risk for men with calcitonin or denosumab, nonvertebral fracture risk for men with alendronate, or clinical fracture risk for men with zoledronic acid treatment. The meta-analysis findings for bisphosphonates when considered as a treatment category demonstrated significantly lower risk of vertebral and nonvertebral fractures but not clinical vertebral or clinical fractures. The results for significant reduction in the RR of nonvertebral fractures with bisphosphonate therapy were sensitive to the removal of one study that demonstrated significantly lower risk of nonvertebral fracture for men with risedronate therapy. 30 There were insufficient data to perform metaanalyses for the efficacy of calcitriol, monofluorophosphate, parathyroid hormone, strontium ranelate, or teriparatide for reducing fracture risk in men.
The meta-analyses were limited by the number of similar studies assessing each medication, with only two studies included in each separate meta-analysis of individual medications performed, and three to six studies included in each separate meta-analysis performed for different fracture outcomes when evaluating bisphosphonates as a treatment category. Additionally, many of the included studies in the meta-analyses had small sample sizes. Furthermore, although one included study demonstrated significantly lower morphometric vertebral fracture risk with zoledronic acid treatment, 36 there were not two studies similar enough to perform a meta-analysis for the efficacy of zoledronic acid treatment on fracture outcomes for men. Moreover, the systematic review and meta-analysis findings are limited by the caveat that all included studies were assessed as having unclear or high risk of bias. Despite these limitations, the findings suggest that, in the absence of additional evidence, bisphosphonates should be used as first-line osteoporosis treatment for men given evidence of their efficacy in reducing vertebral fracture risk, and possibly nonvertebral fracture risk. The findings of bisphosphonate efficacy in reducing fracture risk in men apply to individuals with osteoporosis or low BMD according to dual X-ray absorptiometry (DXA) criteria or who have had a prior osteoporotic fracture, because the studies included in this systematic review and meta-analysis included participants who met these criteria. Further studies are needed to evaluate the efficacy of osteoporosis treatment for men with risk factors for fracture who are not known to have osteoporosis or low BMD according to DXA criteria or prior osteoporotic fracture.
This study highlights the need for additional highquality randomized clinical studies of osteoporosis treatment efficacy for men that are sufficiently powered for fracture outcomes, particularly for nonvertebral fracture outcomes, and for nonbisphosphonate treatment options such as denosumab or teriparatide. The findings also highlight the lack of active comparator randomized clinical trials of osteoporosis treatment for men; additional studies of osteoporosis treatment for men with active comparators would help clarify the relative efficacy of different treatment options for reducing fracture risk. These findings also reveal the need for greater diversity of participants in clinical trials of osteoporosis treatment for men; most included studies had largely white study participant populations. Finally, no included study had a duration longer than 3 years, and thus the efficacy of longer osteoporosis treatment duration to reduce fracture risk for men is unknown; additional studies with longer durations would be helpful to evaluate the effect of osteoporosis treatment for longer than 3 years on fracture risk for men, similar to longerduration osteoporosis treatment studies that have demonstrated fracture risk reduction benefit for women. 39 This study has several notable strengths. It is the most comprehensive systematic review and meta-analysis of randomized clinical trials of osteoporosis treatment efficacy for reducing fracture risk for men. A prior systematic review and meta-analysis on the topic of osteoporosis treatment efficacy for men published in 2011 included only five studies that reported fracture outcomes and concluded that the evidence of the efficacy of osteoporosis treatment to reduce fracture risk in men was inconclusive. 40 The current systematic review and meta-analysis, which included 22 randomized clinical studies of osteoporosis treatment for men that reported fracture outcomes, found evidence for the efficacy of bisphosphonate medications for reducing risk of vertebral fractures and possibly nonvertebral fractures in men. Another strength of this study was the assessment of risk of bias of individual randomized clinical trials included in the systematic review using criteria that the Cochrane Collaboration has recommended.
In conclusion, these findings support the use of bisphosphonates to reduce vertebral and possibly nonvertebral fracture risk for men with osteoporosis. Further studies are needed to evaluate the efficacy of bisphosphonates for reducing nonvertebral fracture risk for men and to evaluate the efficacy of nonbisphosphonate treatment options such as denosumab or teriparatide to reduce vertebral and nonvertebral fracture risk for men.
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